FT538 in Subjects With Advanced Hematologic Malignancies
Summary
Third Opinion Trial Synopsis:
This is a study on a new medicine called FT538. They want to see if it works alone for treating acute myeloid leukemia (AML), and if it works with other medicines for multiple myeloma (MM). They plan to increase the amount of medicine given to find the right dose for each disease. They will enroll people in groups based on what they are being treated for.
This is a study on a new medicine called FT538. They want to see if it works alone for treating acute myeloid leukemia (AML), and if it works with other medicines for multiple myeloma (MM). They plan to increase the amount of medicine given to find the right dose for each disease. They will enroll people in groups based on what they are being treated for.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.